Venture Capital

Page 46 of 100

A new credit card for NYC millionaires has over 30,000 people on the waitlist
Newsletters

A new credit card for NYC millionaires has over 30,000 people on the waitlist

By
July 15, 2024
Venture capital could be NATO’s ultimate weapon. Here’s why
Commentary

Venture capital could be NATO’s ultimate weapon. Here’s why

By Klaus Hommels and Fiona Murray
July 12, 2024
AI startups raised $24 billion globally in Q2, but the question remains: Where will value in AI accrue? Here’s one VC’s (slightly) contrarian take.
Newsletters

AI startups raised $24 billion globally in Q2, but the question remains: Where will value in AI accrue? Here’s one VC’s (slightly) contrarian take.

By
July 12, 2024
How we raised $100 million for my Silicon Valley startup in a down market
Commentary

How we raised $100 million for my Silicon Valley startup in a down market

By
July 11, 2024
Exclusive: Armada lands $40 million in funding round led by Microsoft’s M12
Newsletters

Exclusive: Armada lands $40 million in funding round led by Microsoft’s M12

By
July 11, 2024
Andy Dunn, American entrepreneur and the co-founder of Bonobos Inc
Leadership

Ask Andy: Can generative AI solve a startup’s problems?

By
July 11, 2024
Hannah Seal
Tech

The European VC wunderkind behind Mistral, Revolut and Slack just raised $2.3 billion and predicts the AI revolution is only in ‘the earliest innings’

By
July 10, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Newsletters

As more and more weight-loss startups prescribe Ozempic and Wegovy, doctors say they’re making unproven claims

By Jessica Mathews and Alena Botros
July 10, 2024
A person using Ozempic on November 2, 2023, in Madrid, Spain. Novo Nordisk, the Danish firm that manufactures Ozempic, has reported record quarterly results, up almost 3% on the stock market. The company's revenues rose by 38% to DKK 58.73 billion, some 7.8 billion euros. Ozempic is a diabetic drug that causes a loss of up to 15% of body weight because it acts as an appetite suppressant, a side effect that has made the drug fashionable on social media as a weight loss drug.
Features

Ozempic and Wegovy are marketed as a short-term holy grail for weight loss by some startups. Doctors disagree

By Jessica Mathews and Alena Botros
July 9, 2024
Exclusive: Canoe Intelligence raises $36 million for Series C led by Goldman Sachs
Newsletters

Exclusive: Canoe Intelligence raises $36 million for Series C led by Goldman Sachs

By
July 9, 2024
Odyssey cofounders Oliver Cameron and Jeff Hawke.
Tech

Two self-driving car guys take on OpenAI’s Sora, Kling, and Runway to be Hollywood’s favorite AI

By
July 8, 2024
How whaling ventures in the 1800s shaped venture capital as we know it
Newsletters

How whaling ventures in the 1800s shaped venture capital as we know it

By
July 8, 2024
Peter Thiel’s doping-friendly Olympics alternative—the Enhanced Games—is in talks to raise $300 million as it prepares its first edition
Finance

Peter Thiel’s doping-friendly Olympics alternative—the Enhanced Games—is in talks to raise $300 million as it prepares its first edition

By Mark Bergen, Eyk Henning and Bloomberg
July 5, 2024
Fintech is likely to face increased scrutiny after Evolve hack
Newsletters

Fintech is likely to face increased scrutiny after Evolve hack

By
July 5, 2024
Why Universal Hydrogen folded—and why the company’s mission will live on
Newsletters

Why Universal Hydrogen folded—and why the company’s mission will live on

By
July 3, 2024

Most Popular